University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Masters Theses

Dissertations and Theses

November 2016

Investigating the Balance Between Estrogen Receptor Mediated
Cell Proliferation and Genomic Surveillance
Margarita Brown
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/masters_theses_2
Part of the Molecular Biology Commons, and the Other Animal Sciences Commons

Recommended Citation
Brown, Margarita, "Investigating the Balance Between Estrogen Receptor Mediated Cell Proliferation and
Genomic Surveillance" (2016). Masters Theses. 410.
https://doi.org/10.7275/9042640 https://scholarworks.umass.edu/masters_theses_2/410

This Open Access Thesis is brought to you for free and open access by the Dissertations and Theses at
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Masters Theses by an authorized
administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.

Investigating the Balance Between Estrogen Receptor Mediated Cell
Proliferation and Genomic Surveillance

A Thesis Presented
by
MARGARITA M. BROWN

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of
MASTER OF SCIENCE
September 2016
Animal Biotechnology and Biomedical Sciences

i

Investigating the Balance Between Estrogen Receptor Mediated Cell
Proliferation and Genomic Surveillance

A Thesis Presented
By
MARGARITA M. BROWN

Approved as to style and content by:

Karen A. Dunphy, Chair

Sallie W. Schneider, Member

Laura N. Vandenberg, Member

Rafael A. Fissore, Department Head
Veterinary and Animal Sciences Department

ii

DEDICATION

To my mentors and all that my find this work useful.

iii

ACKNOWLEDGEMENTS

I would like to thank my advisors Dr. Jerry, Dr. Dunphy and Amy Roberts
for their tireless support of my goals. Thank you to my lab mates for reminding
me to have fun. Thank you to my family for keeping me focused on what is
important.

iv

ABSTRACT

INVESTIGATING THE BALANCE BETWEEN ESTROGEN RECEPTOR
MEDIATED CELL PROLIFERATION AND GENOMIC SURVEILLANCE
SEPTEMBER 2016
MARGARITA M. BROWN, B.A., MOUNT HOLYOKE COLLEGE
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Dr. Karen A. Dunphy
Breast cancer is a leading cause of cancer in women and the second leading
cause of cancer death. Lifetime exposure to estrogen contributes to this risk but
high dose estrogen has been used to induce apoptosis as treatment for breast
cancer. These opposing tumorigenic and anti-tumorigenic effects of estrogen
may be regulated differently by the two Estrogen Receptors (ER), Estrogen
Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). Although the receptors
share a 96% homology in their DNA binding domain, they are unique in the
ligand-binding domain with 53% amino acid homology. Previous studies have
shown that ERα drives cell proliferation in the mammary gland. We propose that
ERβ mediates genomic surveillance in the mammary gland to restrict
proliferation. To test this hypothesis we first characterized each of our reference
breast cancer cell lines to determine the ERα and ERβstatus. We found that ERβ
transcript and protein are expressed in some breast cancer cell lines that are
considered to be “triple-negative” (HCC1937 and MDA MB 231). Using specific
v

ER agonists, we were able to demonstrate that amphiregulin, a secreted protein
and a marker of ERα activation, is upregulated by ERα agonists in a dose
dependent manner in cell lines that have ERα (T47D & MCF7). ERα agonists do
not enhance AREG expression in cell lines that primarily expresses ERβ
(HCC1937). Instead, CEBPd, a tumor suppressor, is expressed at high levels in
this cell line. In conclusion, targeting ERβ has the potential to selectively activate
tumor suppressor pathways without stimulating proliferation and may provide a
treatment option for patients for whom inhibition of ERα is not an option.
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CHAPTER 1

INTRODUCTION
The Dual Roles of Estrogen
Globally, the most common cancer in women is breast cancer. In the
United States, the probability of a woman developing breast cancer in her
lifespan is 1 in 8 (Siegel, 2015). Although many factors play a role in the
occurrence of cancer, including a woman’s genetics and lifestyle choices, the
greatest contribution to breast cancer risk in a lifetime stems from chronic
exposure to estrogen (K. N. Anderson, Schwab, & Martinez, 2014).
Estrogen has duplicitous effects in the breast, in that it both promotes and
reduces breast cancer risk (Folkerd E, 2013). Early menarche, late menopause
and estrogen exposure post-menopause promote breast cancer risk, while an
early full term pregnancy reduces that risk by 50% (MacMahon et al., 1970). In
vivo studies in rats using estrogen and progesterone to mimic levels during
pregnancy showed a reduction in the incidence of mammary tumors (Cabanes et
al., 2004; Rajkumar et al., 2001; Sivaraman et al., 1998). Also, parous and
hormone treated mice had a greater apoptotic response to ionizing radiation
compared to nulliparous mice (Dunphy KA, 2008). High doses of estrogen have
also been used successfully to treat breast cancer in postmenopausal women by
increasing apoptosis and decreasing tumor size (G. L. Anderson et al., 2012;
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Ellis et al., 2009; Haddow, Watkinson, Paterson, & Koller, 1944). These dual
roles indicate a potential balance between estrogen-mediated pathways that
regulate proliferation versus genomic surveillance facilitated by cell cycle arrest
and apoptosis. The opposition of effects between activation and abatement of
proliferation might be regulated by different estrogen receptors in order to
maintain the homeostatic balance within the mammary epithelium.
Estrogen signals via two receptors, Estrogen receptor alpha (ERα) and
Estrogen receptor beta (ERβ), to regulate gene transcription (Gruber, Gruber,
Gruber, Wieser, & Huber, 2004). Two ligand bound estrogen receptors located in
the nucleus dimerize and bind to an estrogen response element (ERE) on DNA.
Recruitment of co-activators and co-repressors interacting with the DNA bound
estrogen receptor-ligand complex assist in transcription regulation in tissues
(Kurebayashi et al., 2000). Estrogen receptors can homodimerize forming an
ERα-ERα or ERβ-ERβ complex; or they can heterodimerize as ERα-ERβ
(Ogawa et al., 1998). Dimerization of the different homodimers and heterodimers
could elicit different effects in the regulation and transcription of genes (Monroe
et al., 2005).
Two separate genes, ESR1 and ESR2, encode ERα and ERβ
respectively. Estrogen receptors have four functional domains and a hinge region
(Figure 1.1). The N-terminal domain (A/B) is regulatory, and contains an
activation function region (AF-1) that coordinates the receptors interaction with
transcription factors (Metzger, Ali, Bornert, & Chambon, 1995) .The DNA binding
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domain (C/D) is highly conserved between both ERα and ERβ and the receptors
share a 96% conserved region that binds to the hormone response element on
DNA. The hinge region (D) gives the receptor flexibility between the DNA binding
domain and ligand binding domain. The E/F domain contains both the ligand
binding pocket and the AF-2 region that directly contacts coactivator peptides.
The function of the F domain on the C-terminal is still being investigated. Though
the two ERs are similar in their DNA binding region, they are distinct in their
ligand-binding domain with only 53% homology (Reese et al., 2014). Because the
DNA binding domain is highly conserved (96%) between ERα and ERβ, both
receptors have similar affinity for the ERE (Klinge, 2001). However, because the
ligand-binding domain is distinct (53%) between ERα and ERβ, this region
confers ligand specificity to each receptor that can be used to stimulate one
receptor and not the other.
ERα and ERβ have distinct tissue expression patterns in different tissues
of the body. Regionally, ERα is expressed in the pituitary gland and the uterus
while ERβ is predominately found in the lungs and the bladder. Both receptors
are expressed in the normal mammary gland (Mueller & Korach, 2001). ERα is
expressed in 15-30% of luminal epithelial cells while ERβ is expressed in luminal
epithelial, myoepithelial, fibroblasts and adipocytes (Figure 1.2)(Anderson, 2002).
Interestingly, ER positive status is lost during cancer progression and in many
breast cancer cell lines (Park P 2001, Shaaban AM 2003, Roger P 2001, Bardin
2004). The ER positive phenotype is also progressively lost in primary cell culture

3

of human breast cancer tumors (V. Speirs, 1998). Confirming ERα and ERβ
status in ER positive cell lines: T47D, MCF-7, ZR 75-1, 76N TERT and in ER
negative cell lines: MDA 231 and HCC1937, as well as assessment of an ERβ
inducible cell line: MCF-7 –tetracycline-repressible ERβ (MTO ERβ), will
cumulatively be powerful in vitro tools for the assessment of growth responses
based on ER ratios (Figure 1.3).
Both receptors bind 17β-estradiol (E2), the endogenous ligand, with an
equal affinity (Figure 1.4). Estrogen receptor ligands with specific affinities for
ERα or ERβ exist. All estrogen receptor agonists are measured in relation to the
competitive binding between E2 and the competitor. The ERα specific ligand,
Propyl-pyrazole-triol (PPT) shows >410-fold selectivity for ERα over ERβ.
Whereas 7-Ethenyl-2- (3-fluoro-4-hydroxyphenyl)-5-benzoxazolol (ERB041) and
Diarylpropionitrile (DPN) display >200-fold and 70-fold selectivity for ERβ over
ERα, respectively (Kuiper et al., 1997). Using ER specific ligands to bind to
either ERα or ERβ will give us the ability to examine the distinct transcriptional
properties of the receptors in the context of the different cell lines.
Estrogen receptor selective agonists have been used in the past to study
both the balance of ERα and ERβ in cell lines as well as the expression of their
target genes. One study used a tetracycline inducible ERβ variant of the human
osteosarcoma line (U2OS) to measure how the ratio of ERα and ERβ effected
cell proliferation induced by E2, the ERα agonists PPT, and the ERβ agonist
DPN. They found that increasing the expression of ERβ and adding the ERβ
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agonist DPN corresponded to curbed cell proliferation when compared to cells
treated with E2. Also, they found that the addition of the ERα agonist PPT to the
cells, regardless of ER expression, would stimulate cell proliferation (Sotoca et
al., 2008). Another study used the breast cancer cell line MCF-7 to investigate
the transcriptional profiles of ERα and ERβ stimulation. MCF-7 cells that were
treated with E2 were shown to up regulate genes that signal for cellular
proliferation including Amphiregulin (AREG) while simultaneously down
regulating Transforming growth factor beta (TGFβ), a cytokine that restricts cell
growth (Frasor et al., 2003). An additional study found that ERβ specific
stimulation by DPN increases the PTEN tumor suppressor in MCF-7 and T47D
breast cancer cell lines (Lindberg, Helguero, Omoto, Gustafsson, & Haldosen,
2011). This indicates that there are specific estrogen receptor roles in the
regulation of cell proliferation.
Breast cancer is grouped by receptor status through immunohistological
(IHC) characterization. Broadly, breast tissues stain positively for estrogen
receptor alpha (ERα+) and progesterone receptor (PR+) are classified as
“Receptor Positive” or “Luminal Type” breast cancer. Currently, therapeutics that
antagonize the estrogen receptor exist and prognosis is generally good. Targeted
therapeutics are also available for breast cancers that stain positively for HER2/neu (HER-2+). Unfortunately, 15% of breast cancers do not stain for any
receptor and are classified as triple negative breast cancer (TNBC)(Chacón &
Costanzo, 2010). TNBC is more likely to reoccur and has the poorest prognosis
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because there are no targeted treatments available. Though both ERα and ERβ
are expressed in the mammary gland (Kuiper GG, 2007), only ERα is routinely
tested for (Allred, 2010). However, the ER content of breast tumors that were
categorized as triple negative (TNBC) has been investigated and it was
determined that up to 25% of TNBCs expressed ERβ (Reese et al., 2014).
Therefore, ERβ targeted therapy is a potential option to elicit a genomic
surveillance response and cell cycle arrest in TNBC.
The dual roles for estrogens and their contribution to genomic surveillance
and proliferation have been investigated previously in the Jerry lab. BALB/cTrp53+/+ mice were ovariectomized and allowed to recover and clear endogenous
hormones for one week. They received daily intraperitoneal injections for 4 days
with vehicle, E2 (2ug), progesterone (P; 200ug) and an E2+P combination and
were subjected to 5Gy ionizing radiation prior to tissue harvest (Becker et al.,
2005). Nuclear protein expression of radiation-induced p21, a cell cycle inhibitor,
was upregulated to the greatest extent in the E2 or E2+P treatment groups
compared to vehicle and P alone. Furthermore, treatment with E2+P + ICI
182,780 (an estrogen receptor inhibitor) mirrored the lower radiation-induced p21
response to progesterone alone. E2+P +mifepristone (an inhibitor of
progesterone receptor) retained a strong p21 response to ionizing radiation. This
indicated that the estrogen receptor was necessary to fully potentiate radiationinduced genomic surveillance cell cycle arrest pathways.
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To examine the contribution of the two estrogen receptors, ERα and ERβ,
in terms of proliferation and genomic surveillance responses, ovariectomized
BALB/c mice were implanted with silastic capsules containing cellulose (Control)
or cellulose with Progesterone (20mg) together with E2 (50ug), or one of the ER
selective agonists: for ERα - PPT (400ug) and for ERβ - DPN (400ug) (Erick
Roman-Perez, unpublished. After 3 days, mice were subjected to ionizing
radiation. Apoptotic responses were increased to a similar extent by all hormones
when compared to control (Figure 1.5a). However, the only E2+P and PPT+P
increased proliferation as determined by BrdU incorporation and amphiregulin
expression (Figure 1.5b). The ERβ agonist, DPN failed to activate proliferation.
Roman-Perez et al concluded that the ERβ specific agonists (DPN) could
activate genomic surveillance via induction of apoptosis in response to radiation
without inducing proliferation.
Hypothesis and Rationale
Estrogen bound to an Estrogen Receptor can stimulate proliferation and to
enhance genomic surveillance to prevent the unwanted proliferation of damaged
cells. These dual roles are central to the paradox of estrogen- the ability of
estrogen to both promote and inhibit breast cancers. This is possibly due to the
ratio of the two estrogen receptors, alpha and beta, and their ability to balance
estrogen-mediated proliferation with genomic surveillance to activate apoptosis
or cell cycle arrest. The two estrogen receptors are 96% homologous in their
DNA binding domain, meaning that they bind to similar estrogen response
7

elements on DNA, but are distinctive in their ligand-binding domain with 53%
amino acid homology. This means that the two different estrogen receptors can
be selectively targeted with selective estrogen receptor agonists.
Specific estrogen receptor agonists have been used in the past to
compare Estrogen Receptor responses in vitro using human breast cancer cell
lines and in vivo using mouse models. Preliminary data in mice show that
radiation induced apoptosis is increased with estrogen receptor agonists
(Roman-Perez, unpublished). Only the ERβ specific agonist could induce
apoptosis without activating proliferation.
Hypothesis: Specific activation of ERβ in the human mammary gland selectively
activates genes that mediate genomic surveillance without stimulating
proliferation.
Several Estrogen Receptor targets are of interest to breast cancer
research because of their association with cell proliferation or genomic
surveillance (Figure 1.6). The ERα associated protein amphiregulin (AREG) is of
interest because it is an effector of estrogen signals and it works in a paracrine
fashion to promote growth in neighboring epithelial cells (Peterson et al., 2015). A
second target of interest is the Progesterone Receptor (PR) which is positively
regulated by ERα ligand-dependent activation (Lin et al., 2004).
ERβ mediated growth restriction may occur by regulating the expression
of cytokines and transcription factors. One cytokine of interest that may be
modulated by ERβ is transforming growth factor beta 2 (TGFβ2). TGFβ2 is a
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estrogen stimulated growth repressor that has been suggested to be regulated by
ERβ in rat prostates (Itoh, Patel, Cupp, & Skinner, 1998). The transcription factor
CCAAT/Enhancer Binding Protein (CEBPD) is also of interest because it is
expressed in mammary luminal epithelial cells during involution and co-regulates
pro-apoptotic genes (Thangaraju et al., 2005; Yu, Si, Zhang, & DeWille, 2010).
Investigating the targets of Estrogen Receptors may help elucidate the molecular
events that govern breast cancer cell proliferation and genomic surveillance.
Targeting a hormone receptor has been a successful therapy for breast
cancer for patients who test positive for ERα, PR or Her2. Current targeted
therapies for Estrogen Receptor positive breast cancer aim to inhibit the
proliferative effects of ERα. There are no targeted therapies for Triple Negative
Breast Cancer (TNBCs), which lack ERα, progesterone receptor (PGR) and
human epidermal growth factor receptor 2 (HER2). TNBCs have poor prognosis.
However, some TNBCs express ERβ. Targeting ERβ has the potential to
selectively activate surveillance pathways without stimulating proliferation and
may provide a treatment option for patients for whom inhibition of ERα is not an
option (both ERα+ non-responders and TNBCs). Further, the expression of a
higher ratio of ERβ to ERα may be important to an increased disease-free and
overall survival in patients with triple negative breast cancer (Honma et al., 2008).
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Objectives
Objective 1. Characterize the ratios of ERα and ERβ in cell lines by gene
and protein expression.
Luminal type: MCF-7, T47D, ZR75-1, MTO ERβ
Triple negative breast cancer: MDA-MB-231, HCC 1937
“Normal”: 76N Tert
Objective 2: Compare responses to different estrogen receptor agonists in
breast cancer cell lines in vitro.
•

Cell proliferation measured against cell death

•

Gene expression of proliferation genes vs. surveillance genes

Objective 3: Conduct an in vivo experiment using the βERKO mouse model
to explicate the histologic and gene expression profiles of acute agonist
exposure in mouse mammary tissue for proliferation and markers of
surveillance.
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Figure 1.1 Structure and Homology of the Estrogen Receptors.
Estrogen Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). ERα
and ERβ share a 96% amino acid homology in their DNA binding domain
(DBD). They are distinctive in their activation function domain (AF-1, 30%
homology), hinge domain (D; 30% homology) and in their ligand-binding
domain (LBD/AF-2; E/F; 53% homology). The differences in these domains
confer both ligand binding specificity as well as distinct transactivation
functions to the receptors, allowing for the recruitment of transcription
factors that mediate cell proliferation and genomic surveillance.
Adapted fron Roman-Blas, J. A., Casteneda , S., Largo, R., & HerreroBeaumont, G. (2009). Osteoarthritis associated with estrogen
deficiency. Arthritis Res Ther, 11(5), 241.
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a
b
c

d
Figure 1.2 Expression of ERβ in human mammary gland.
Immunohistochemistry (IHC) of a human mammary gland using 14C8 ERβ
antibody shows that ERβ is expressed in fibroblasts (a), myoepithelial cells
(b), luminal cells (c) and adipocytes (d).
Photo by Karen Dunphy
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Cell Line

ER PR Her2

P53

T47D

+

+

+

leu to phe

MCF-7

+

+

+

wt

MDA MB 231

-

-

-

arg to lys

MCF-7 MTO ERB Repressed

+

+

+

wt

HCC1937

-

-

-

mutant (stop)

ZR75-1

+

+

+

wt

76N tert

+

+

n/a

wt

MCF-7 MTO ERB Expressed

+

+

+

wt

HeLa

-

+

-

wt

Figure 1.3 Table of Breast Cancer Cell Line Characteristics.
Soussi, Thierry. "Handbook of p53 mutation in cell lines." Version
1, no. 07 (2007): 2007.
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Figure 1.4 Estrogen Receptor Agonists. Endogenous and
exogenous ligands for the estrogen receptor and their relative binding
affinities for the different receptors relative to 17β-estradiol.
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Radia/on-Induced Apoptosis in BALB/c
Mammary Epithelium

b

Prolifera/on in BALB/c Mammary
Epithelium

Percent of BrdU Posi/ve Cells

a
.

25
20
15
10
5
0
Control

E+P

PPT+P

DPN+P

Figure 1.5 Proliferation and Apoptosis in the BALB/c Mouse
Mammary Gland in Response to Agonists. Estrogen receptor
agonists 17β-estradiol (E), 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5triyl)trisphenol (PPT) and Diarylpropionitrile (DPN) increase
radiation induced apoptosis response in BALBc mice when
combined with progesterone (P) to mimic the protective effect of
parity (a), but only 17β-estradiol and PPT induce proliferation
(b), DPN a potent Estrogen Receptor β agonist failed to induce
proliferation.
Erick Roman-Perez, et al. unpublished
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What markers ER mediated response will be used?
ERα responsive target:
ERβ responsive targets:
• Progesterone receptor (PR) – ac6va6on • WNT5a - regulatory aﬀect on growth
by ERα
• Transforming growth factor- beta 2
ERβ
• Amphiregulin (AREG) – prolifera6on
(TGFβ2) – cellERα
cycle arrest
TGFβ2
WNT5A
Luminal
Myoepithelial
Basement Membrane
Fibroblast
Adipose
Blood Vessel

TGFβ2

AREG

AREG

CEBPD

ERβ

PR
ERα

E2
ERB041 PPT
DPN
Figure 1.6 Model depicting hypothesis whereby estradiol
stimulates proliferation or genomic surveillance by regulating
gene expression including cytokines.
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CHAPTER 2
CHARACTERIZATION OF THE RATIOS OF ERα AND ERβ IN CELL LINES BY
GENE AND PROTEIN EXPRESSION
Introduction/Rationale
Examining the expression of ERα and ERβ across cell lines is important
because there are conflicts with regard to the ER status of human breast cancer
cell lines in the literature (Figure 2.1 a&b). For example, the MCF-7 cell line is
regarded as a model of an exclusively ERα positive cell line (Felzen et al., 2015;
Hsieh, Santell, Haslam, & Helferich, 1998). Yet some report that the MCF-7cell
line also expressed ERβ (Tong et al., 2002; Vladusic, Hornby, Guerra-Vladusic,
Lakins, & Lupu, 2000). Further, the MDA MB 231 cell line is used as a model for
ER negative breast cancers (Price, Polyzos, Dan Zhang, & Daniels, 1990) and
published data from three sources, using both RT-PCR and western blot assays,
find that the MDA MB 231 cell line, are, in fact, ERα negative (Kao et al., 2009;
Subik et al., 2010; Tong et al., 2002). However, other published reports
demonstrate that MDA MB 231 is both ERα (Ford, Al-Bader, Al-Ayadhi, &
Francis, 2011) and ERβ positive (Ford et al., 2011; Tong et al., 2002).
Establishing ER status in our reference cell lines is necessary for the examination
of the ER agonist responses. The selected human cell lines represent “normal”
breast epithelium (76N Tert), luminal type breast cancers (MCF-7, T47D, ZR75-1,
MTO ERβ) and TNBCs (MDA-MB-231, HCC 1937). To compare the ratios of the
17

receptors, expression of ESR1 and ESR2, the genes for ERα and ERβ
respectively, will be assessed using qPCR and protein will be evaluated with
western blots. Primers for qPCR amplification are included in Figure 2.2.
Detection of ERα expression was accomplished using the historically
validated antibody SC-542 (MC-20), a polyclonal rabbit ERα antibody from Santa
Cruz (Karen A. Dunphy et al., 2013). Immunohistochemical and western blot
detection of ERβ has been unreliable in the past because the available
antibodies are inconsistent (Skliris et al., 2002). Recently, a paper from the
Mercurio lab at UMass Medical School investigated how the loss of ERβ effected
chronic inflammation in human prostates (Mak, Li, Samanta, & Mercurio, 2015).
They used the GeneTex ERβ antibody GTX112927 to observe ERβ expression in
prostate cell lines. This rabbit polyclonal antibody was made against a
recombinant peptide sequence within the center region of human ERβ (Figure
2.3). Additionally, because western blot detection and specificity of ERβ
antibodies have been inconsistent in the past, we will also consider the primary
antibodies GTX70174 (GeneTex) mouse monoclonal antibody, clone 14C8,
developed against aa 1-153 of human ERβ, PA1-311 (Thermo Scientific) rabbit
polyclonal, immunogen aa 55-70 of rat ERβ and PA1-310B (Thermo Scientific)
rabbit polyclonal, immunogen aa 467-485 as potential options for assessing ERβ
expression in human cell lines (Figure 2.3).
There are five described isoforms of ERβ, of which only ERβ1 contains a
functional ligand-binding domain capable of binding hormone (Leung, Mak,
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Hassan, & Ho, 2006). Three of the antibodies (GTX112927, GTX70174 and PA1311) will bind all isoforms of ERβ while only PA1-310B will bind to the unique
intact C-terminal end of ERβ1 (Figure 2.3). ERβ2, 4 and 5 do not have the ability
to increase gene activation on their own, they must dimerize with ERβ1. It is
therefore useful to include primary antibodies that are able to recognize
functional ERβ1 in this study.
The efficacy and specificity of the ERβ antibodies will be assessed using
the inducible ERβ cell line MCF-7 Tet-Off (MTO ERβ) as a positive control. MTO
ERβ is a human breast cancer derived cell line stably transfected with
tetracycline repressible estrogen receptor beta. The cells express a tetracycline
regulated Tet-Off transactivator. Inducible expression of ERβ occurs when
doxycycline (dox) is withdrawn from the culture medium. Conversely, in the
presence of dox, ERβ expression is repressed. The inducible MTO ERβ is a
good positive control for ERβ because we can regulate ERβ expression and have
already determined the doses of doxycycline for efficient repression of ERβ
(Figure 2.4). As a negative control, the human cervical adenocarcinoma derived
cell line HeLa, was used, as it is negative for both ERα and ERβ (Holliday &
Speirs, 2011).
Materials and Methods
Cell Culture: T47D and MDA MB 231 cells were kindly donated by Dr. Sallie
Schneider. MCF-7 tet off cells were provided by Dr. L. Hodges-Gallagher
(Hodges-Gallagher et. al., 2007); ZR 75-1 from Dr. Charles Perou, 76N tert cells
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from Dr. Vimla Band, Hela cells from Dr. Rong Shao. HCC1937 were purchased
from ATCC. All cells were cultured at 37°C and 5% CO2. Each Cell line was
expanded in their standard Dulbecco’s Modified Eagle’s Medium/Nutrient mixture
F1-12 Ham (DMEM:F12, Sigma-Aldrich; St. Louis, MO) with 15 mM NaHCO3 and
25 mM Hepes. Cells were plated in triplicate, either at 500,000 cells/well or
1,000,000 cells/well in a six well plate (Cell Treat; Shirley, MA) at 50-60%
confluence in order to achieve optimum 75-80% cell density after 24hrs of
incubation. The cells were harvested for mRNA (three replicates) or lysates
(three replicates). To repress the expression of ERβ in the MCF-7 tet off cells,
cells were maintained in 50 ng/ml Doxycycline (Dox)(Sigma-Aldrich; St. Louis,
MO). To repress ERα, cells were treated with 10nm ICI 182,780, 10nm E2 or
both.
Primer Design and Efficiency Determination: Oligonucleotide primers were
designed with software from qPrimerDepot (Dr. Wenwu Cui PhD, National
Institutes of Health) and analyzed using the Integrated DNA Technologies (IDT)
OligoAnalyzer software (Redwood City, CA), with sequences available from the
PubMed database. The primer pairs were selected using the following criteria:
the cDNA amplicon will be about 100 base pairs, primers are designed to flank
intron-exon borders or primers that will anneal at a splice junction to distinguish
genomic DNA from cDNA, primers will have similar annealing temps at or around
60°C, with a G/C content of 20-70% and low or no self-complementarity
sequence. Table 2.2 lists the genes as well as the forward and reverse
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sequence. Primer efficiency was determined by measurement of the gradient of a
standard curve. The log of the target concentration was plotted against the
quantitation cycle. Efficiencies at or close to 100% were accepted.
mRNA Isolation and RT-qPCR: RNA was isolated from cell culture using 1 ml
TRIzol™ reagent (Life Technologies, Carlsbad, CA) per well (6 well plate),
according to the manufacturer’s instructions. Complementary DNA was
synthesized using 1 ug of RNA, d(T)23VN(50μM) and ProtoScript II Reverse
Transcriptase (New England BioLabs Inc., Ipswich, MA). qPCRs were carried out
in a MJ Research PTC-100 thermal cycler (Bio-Rad; Hercules, California).
Quantification of each cDNA was achieved using SYBR Green Master Mix
Reagent (Applied Biosystems; Foster City, CA) in duplicate. Gene expression is
shown relative to T47D cells treated with 10nM ICI as an inter run calibrator
(IRC). Relative quantification was performed using a comparative CT method.
Values shown are relative to the IRC. Ratios of Estrogen Receptors were made
relative to T47D cells.
Western Blotting: Whole cell extracts were lysed using 300μl/well (6 well plate)
of ice-cold RIPA lyses buffer (50 mM Tris–HCl, pH 8.0; 150 mM NaCl; 1 mM
EDTA; 1 % Triton X-100; 1 % Sodium deoxycolate; 0.1 % SDS; 1 % protease
inhibitors (P8340 Sigma-Aldrich; St. Louis, Mo), 1% phosphatase inhibitor
#2(P5726, Sigma-Aldrich; St. Louis, MO), 1% phosphatase inhibitor #3 (P0044
Sigma-Aldrich; St. Louis, Mo) (Sigma-Aldrich; St. Louis, MO). Following
centrifugation of the homogenate for 15 min at 13,000 rpm at 4 °C, the
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supernatant containing the protein was removed from the cellular debris and
quantified by the Bradford method. Equal amounts of protein (20 μg) were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDSPAGE) through 10 % acrylamide under reducing conditions and then blotted onto
Hydrophobic Polyvinylidene Fluoride (PVDF) membrane (Immobilon-P; Millipore,
Watford, United Kingdom). The blot was blocked with a 5 % non-fat dry milk in
TBST (10 mM tris-HCl pH 7.5, 150 mM NaCl, 0.1 % tween-20) for 60 min and
subsequently incubated overnight at 4 °C with polyclonal anti- ERα (Santa Cruz
Biotechnology Inc, MC-20: sc-542; 1:1000), anti-ERβ (Thermo Scientific PA1311B; 1:2000 PA1-310B; 1:1000; GeneTex GTX70174; 1:1500), and anti-β actin
(Sigma A1978; 1:5000). After washing in TBST, the membranes were incubated
with a horseradish peroxidase-conjugated secondary antibody (1:5000) for 1 h.
The bands were visualized by enhanced chemiluminescence (100 mM Tris/HCl
pH 8.5, 250 mM luminol (Sigma,Aldrich; St. Louis, MO), 90 mM p-coumaric acid
(Sigma-Aldrich; St. Louis, MO), 30% hydrogen peroxide(Sigma-Aldrich; St.
Louis, MO), imaged using G:BOX (Synoptics Ltd; Frederick, MD) and quantified
using GeneTools analysis software from Syngene (Synoptics Ltd; Frederick,
MD). The expected molecular weight for the protein product for the western blot
is 66 kDa for ERα, 59 kDa for ERβ and 42 kDa for the β actin loading control. All
cell lines were run in two independent experiments, each cell line band was
quantified using average luminescence and compared relative to the T47D cell
line.
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Ratio of ESR2: ESR1 and ERβ: ERα: Expression was set relative to T47D cells.
Assuming ESR2: ESR1 and ERβ: ERα is 1:1 in T47D cells, the ratio for each cell
line were determined. These were calculated by comparing relative values. For
example ESR2: ESR1 in MCF-7 parental cells: ESR2 0.12/ ESR1 1.13 = 0.106.
Likewise for ERβ: ERα, this was calculated by comparing relative values in MCF7 parental cells: ERβ 1.29/ ERα 0.46 = 2.8.
Statistics: A two sided students t-test was used to determine differences relative
to T47D cells. A p-value <0.05 (*) was considered significant and <0.01 (**)
considered highly significant. Error bars indicate SEM.

Results
ESR1 and ESR2 have a distinct expression across cell lines
ESR1 and ESR2 expression was evaluated using cDNA generated from
the RNA harvested from the individually cultured cell lines (Figure 2.5 a&b).
Expression is relative to T47D cells because they were expected to express both
ERα and ERβ (Ford et al., 2011). ESR1, encoding Estrogen Receptor alpha, was
expressed to a similar level in T47D, MCF-7 parental cell line as well as the MTO
ERβ cell line, regardless of whether ERβ was expressed or repressed. The cell
line ZR 75-1 and the triple negative cell line HCC1937 had about 50% of the
ESR1 expression as T47D. The other triple negative cell line, MDA MB 231, had
very little expression and interestingly the “normal” epithelial cell line, 76N tert,
also has very low ESR1 expression (p<0.05).
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ESR2 expression in the ZR 75-1 and the 76N tert cell line is similar to the
T47D cell line (Figure 2.5b). The triple negative cell lines MDA MB 231 and HCC
1937 have significantly greater ESR2 expression, with levels that are ~9-fold
and ~12.5-fold, respectively, greater than T47D (p<0.01). The parental MCF-7
cell line has considerably lower ESR2 expression than T47D , but the decrease is
not significant. The MCF-7 ERβ repressed cell line has six-fold greater ESR2
expression when compared to T47D (p<0.01). This is probably due to leaky
expression of the ESR2 gene, even in the presence of doxycycline. Predictably,
in the absence of doxycycline, the MCF-7 ERβ expressed cell line had greater
than 200-fold increase in ESR2 expression compared to T47D.
Validation of Estrogen receptor beta antibodies
There was a need to evaluate several ERβ antibodies for western blotting.
The primary antibodies GTX70174, PA1-311 and PA1-310B were evaluated.
ERβ has a calculated molecular weight of about 55-59 kDa in western blots. The
antibody from GeneTex, GTX70174, failed to show a band on a western blot. In
contrast, a band was visualized with the antibody PA1-311 from Thermo
Scientific, but the suspicion is that the band was non-specific binding of the
antibody. Comparison of the band to the Dual Color Precision Plus Protein™
Standard (BioRad; Hercules, California) showed a product with a molecular
weight of 66-69 kDa (Figure 2.6 a). Additionally, product was detected with the
PA1-311 antibody in the estrogen receptor negative HeLa cells. The PA1-310B
antibody detected a ~47kDa product (Figure 2.6 b) in MCF-7 cells, MCF-7 cells
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transfected with ERβ1 and the T47D cells, but did not detect any product in either
the ovaries from βERKO mice or in HeLa cells, which are negative for both
estrogen receptors. Therefore, we used this PA1-310B antibody to quantify the
ERβ protein expression in the breast cancer cell lines.
Relative intensity of Estrogen Receptors Protein
The expression of ERα (MC-20 antibody) and ERβ using the validated
ERβ antibody PA1-310B were determined for all of the cell lines (Figure 2.7 &
2.8). The relative intensities of ERα (2.8 a), ERβ (2.8 b) and β-actin (2.8 c) were
made relative to T47D. Protein expression was not normalized to β-actin, instead
we relied on accurate quantification via Bradford assay and loading of total
protein because each cell line could have different composition of cytoskeletal
elements. Therefore, normalizing protein to β-actin may not reflect true
expression. Each cell line is quite different in behavior and phenotype, but
regardless there are no differences in β-actin (Figure 2.7 & 2.8 c).
Expression of ERα protein was the greatest in the T47D cell line and was
reduced by about 50% in the MCF-7 parental cells (Figure 2.8 a). The MTO ERβ
off and on cells had about half to two-thirds less ERα detected than the MCF-7
parental line, although this difference relative to the parental cell line was not
significant (0.1 and 0.058). The other ERα positive cell line, ZR75-1 and the
“normal-like) 76N tert, expressed 3% and 7% of T47D level of ERα. The triple
negative cell lines MDA MB 231 (2%), HCC1937 (6%) and HeLa (2%) had
marginal expression of ERα.
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Quantification of the ERβ western blots showed that T47D and MCF-7 had
the highest peak intensity (Figure 2.8 b). MTO ERβ off and on had nearly equal
ERβ protein detected, ~70% of MCF-7 parental cells. The triple negative cell
lines MDA MB 231 and HCC1937 had about half as much ERβ expression as
T47D. The cell lines ZR75-1, 76N tert and HeLa failed to produce a detectible
band on the western blot.
Transcript ratios do not directly correlate to protein ratios or levels in
breast cancer cell lines

Because ERβ is proposed to modulate the proliferation activity of ERα (Li
et al., 2004) and relative abundance of the receptor vary in the cell lines, we
wanted to be able to determine ratios of receptor expression. Our objective is to
classify the cell lines based on receptor ratios as those that express both
receptors, or are predominantly ERα-expressing or ERβ-expressing to correlate
to the estrogen response. Therefore, expression of ESR2: ESR1 transcript, as
well as ERβ: ERα protein in each cell line was determined. Presuming that
ESR2: ESR1 and ERβ: ERα were 1:1 in T47D cells, although this is not likely, we
can determine relative ratios of estrogen receptor transcript and protein in each
of the other cell lines (Figure 2.9). Although transcript of ESR1 is equal between
T47D, MCF-7 and MTO cells (Figure 2.5) the expression of ERα is not (Figure
2.8 a) ESR2 transcript was significantly higher in MDA MB 231, MTO and
HCC1937 cells, but surprisingly, ERβ protein was not increased. These
differences are reflected in the different ratios of expression between transcript
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and protein in each cell line. For instance, in MCF-7 cells, the ratio of ESR2:
ESR1 is 0.11, meaning for each unit of ESR2 (relative to T47D) there are 10 units
of ESR1 (relative to T47D). However, the MCF-7 ERβ:ERα ratio shows 2.77
relative units of ERβ to each relative unit of ERα. The MTO ERβ repressed cell
line ratio shows that there are about 5 units of ESR2 for every 1 unit of ESR1 and
a little over 3 units of ERβ:ERα relative to T47D. ESR2 transcript in the MTO
ERβ expressed cell line had over 200 relative units of ESR2: ESR1, yet
surprisingly, peaked at only 5 units of ERβ to ERα protein relative to T47D. The
triple negative cell lines MDA 231 and HCC1937 expressed 182.79 and 23.64
units respectively of ESR2 to ESR1 relative to T47D. ERβ protein levels were
high compared to T47D at 15. 47 and 7.68 units of ERβ ratio, relative to T47D.
Based on these relative ratios of ESR2: ESR1 and ERβ: ERα, we have classified
the cell lines as those that express both receptors (T47D, MCF7, MTO
repressed); those that express a higher ratio of ERβ: ERα (MTO expressed,
MDA 231, HCC1937); and those that have poor expression of ERs (ZR75-1 and
76N tert).
Effect of ICI on ERα in T47D cells
In an attempt to modulate ERα expression we used both ICI 182,780 and
E2 treatment. ICI is known to decrease ERα protein (Oliveira et al., 2003) and
may stabilize ERβ (Montanaro et al., 2005). ICI and E2 were expected to
decrease ERα expression. ICI binds to ERα to target it for degradation. E2
should trigger a negative feedback loop, reducing the amount of ERα protein
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expression. We found that neither ICI nor E2 decreased ERα protein measured
in T47D cells on a western blot (Figure 2.10 a). Quantification of ERβ did
demonstrate stabilization of ERβ protein by ICI treatment, but not with E2 or ICI +
E2 treatment (Figure 2.10 c). Quantification of ERα and β-actin showed no
significant difference between T47D controls, ICI, E2, or ICI + E2 treatments
(Figure 2.10 b & d).
Discussion
It is obvious that mRNA expression and protein expression do no correlate
with each other. We found that ESR1 expression is equivalent between T47D,
MCF-7 parental and MTO cells. But ERα protein in the MCF-7 parental line was
only 50% of the amount of ERα protein relative to T47D. MTO cells were found to
have only about 20-25% of ERα relative to T47D. ESR2 expression is
significantly increased by >6 fold in MTO cells and further increased by greater
than 200 fold in the MTO cells when expression is relived by removing
doxycycline relative to T47D. However, ERβ protein expression is nit increased in
the cell lines relative to T47D cells, even though transcript is abundant.
Our findings confirm that there is no clear correlation found between
Estrogen Receptor mRNA and protein expression in breast cancer cell lines. This
result corroborates with published data in which mRNA expression in thousands
of genes did not predict corresponding protein levels in MCF-7, MDA MB 231 and
three other breast cancer cell lines (Cifani, Kirik, Waldemarson, & James, 2015).
This outcome is partially attributed to the dynamic mRNA and protein synthesis
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environment in which quantitative RNA levels may be fundamentally detached
from protein half-life in the cellular environment (Schwanhausser et al., 2011).
The published data agrees with our results of positive ERα status in MCF7 and T47D cells (Kao et al., 2009; Tong et al., 2002). But the literature differs
with regard to ERβ expression in MCF-7 and T47D cells (Bulzomi et al., 2012;
Davies et al., 2004). Our results suggest that both cell lines express ERβ.
Further, there were two interesting results in regard to the characterization of the
cell lines. One was that our results show that the ERα positive cell line ZR75-1
expressed neither ERα nor ERβ. The second is, that although the MTO ERβ cell
line with ERβ expressed greatly increased transcript, the protein was not
increased. This is in contrast to work done in other labs where the MTO ERβ off
showed no ERβ protein expression and the MTO ERβ on had a clearly defined
band for ERβ expression using a cocktail of 1:1 of the ERβ antibodies 14C8 and
7B10.7 both from GeneTex (Hodges-Gallagher, Valentine, El Bader, & Kushner,
2008). Another surprising result was that neither ICI nor E2 decreased the protein
expression of ERα, but ICI did appear to stabilize ERβ.
Some of the controversy in the literature comes from the detection of ERβ
in western blots. We tried three antibodies: GTX70174 did not have any
detectable bands, PA1-311 detected an antigen with a higher than expected
molecular weight. PA1-311 antibody also detected antigen in the HeLa cell line,
which are known to be ERβ negative. PA1-310B detected an antigen with a lower
molecular weight than expected. PA1-310B was used throughout this study, but
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its specificity for the ERβ receptor is also questionable due to the lack of a strong
band in the MTO cells with ERβ overexpression. Another curiosity is that PA1310B indicated strong expression of ERβ protein in the MCF-7 cell line, although
the ESR2 transcript in this cell line is extremely low. Therefore our confidence
that this antibody is detecting ERβ is also low.
It is standard in clinical practice to define treatments for breast cancer
based on their hormone receptor status. About 15% of breast cancer is classified
as triple negative, so treatments that rely on hormone receptors are not an option
for these patients. Also, receptor testing does not take in to account the ER
subtypes. ERβ is thought to be a tumor suppressor as well as modulate the
transcriptional effects of ERα. ERβ has been found in triple negative breast
cancer. In this study we attempted to confirm the presence and the balance of
the ERα and ERβ in our reference cell lines. This work shows that two TNBC cell
lines do indeed have ESR2 expression on the mRNA and ERβ protein levels.
The TNBC lines MDA MB 231 and HCC1937 expressed 182-fold and 24-fold
more ESR2 than the ESR1 positive cell line T47D (Figure 2.10). These cell lines
also expressed relatively high ratios (~15 and 8 fold more) of ERβ protein in
western blots (Figure 2.10) than T47D. Therefore, targeting ERβ may have a
clinical benefit for TNBC.
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Figure 2.1 Estrogen Receptor alpha (a) and beta (b) status
charts from several sources demonstrate conflicts. T47D,
MCF-7 cells test positive for both ERα and ERβ while MDA MB 231
and HCC1937 cells could be both ERα positive or negative
depending on the source.
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Figure 2.2 Primer sequences used in qPCR.
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GTX70174

GTX112927

PA1-310B

PA1-311
Figure 2.3 Diagram of Estrogen Receptor beta isoforms with
corresponding antibody location on the receptor. ERβ has
five mRNA splice variants. ERβ-cx, cannot bind ligand, due to a
change in helix 12 (LBD), resulting from the alternative splicing of
exon 8 (Ogawa et al., 1998).

Adapted from Adam W. Nelson, Wayne D. Tilley, David E. Neal,
and Jason Carroll “Estrogen receptor beta in prostate cancer:
friend or foe?” Endocr Relat Cancer ERC-13-0508, doi:10.1530/
ERC-13-0508 first published on 8 January 2014.
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ESR2 Repression by Doxycycline in MTO-ERB Cells
1.2
1
0.8
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0

50ng dox

5ng dox

0.5ng dox

0.05ng dox 0.005ng dox

No dox

Figure 2.4 ESR2 Repression by Doxycycline in MTO-ERβ Cells.
The cell line MTO-ERβ (MCF7 tet off ERβ) has a repressible
Estrogen Receptor beta. In the presence of 50ng doxycycline (dox),
expression from a tet-inducible promoter is reduced. As the
concentration of dox is reduced to 0.005ng, the expression of ERβ
increases.
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Figure 2.5 ESR1 (a) and ESR2 (b) Expression in
Human Breast Cancer Cell Lines. Expression of the
receptors is relative to T47D.
* p<0.05; ** p<0.01
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Figure 2.6 Western Blot comparing PA1-311 and PA1-310B
ERβ antibodies. 20μg of whole cell lysate loaded per well.
Lane 1 on both blots is the molecular weight marker. (a)
PA1-311 ERβ antibody detected a band at ~69kDa. (b)
PA1-310B ERβ antibody detected a band at ~47 kDa.
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Figure 2.7 Representative western blot for ERα, ERβ and βactin. Total proteins were resolved using SDS-PAGE and
antibodies for ERα (MC-20), ERβ (PA1-310B) and β-actin
loading control.
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Figure 2.8 Quantification of ERα, ERβ and β-actin in
Human Breast Cancer Cell Lines. Representing four
(ERα and β-actin) and two (ERβ) separate experiments
run independently using different samples of the
representative cell lines. ** p<0.01

38

Express both Estrogen Receptors
T47D
MCF7
MTO ERβ repressed

ESR2/ESR1
1.0
0.11
5.29

ERβ/ERα
1.02
2.77
3.4

Express high ratio of ERβ: ERα
MTO ERβ expressed
MDA231
HCC1937

207.61
182.79
23.64

4.91
15.47
7.68

2.59
25.36

0.00
0

Express negligible ERs
ZR75-1
76N tert

Figure 2.9 Relative Ratios of ESR1: ESR2 and ERα:
ERβ in Human Breast Cancer Cell Lines.
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Figure 2.10 Western blot and Quantification of the relative expression of ERα,
ERβ and β-actin proteins in T47D cells treated with Estrogen Receptor
agonists (a). Quantification of the western blot measuring the effect of ICI on ERα
(b), ERβ (c) and β-actin (d) in T47D cells. *p< 0.05
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CHAPTER 3
COMPARISON OF RESPONSES TO DIFFERENT ESTROGEN RECEPTOR
AGONISTS IN BREAST CANCER CELL LINES IN VITRO.
Introduction/Rationale
Only 15-30% of luminal epithelial cells express estrogen receptors. In
response to estrogens, these cells generate local factors to regulate cell fate and
the development of neighboring cells. ER mediated transcription of genes is
regulated by ligand binding of a specific estrogen receptor agonist (Leitman et al.,
2010; Paruthiyil et al., 2011). Stimulation of ERα, through the binding of its
agonists PPT or E2, mediates cell proliferation (Helguero, Faulds, Gustafsson, &
Haldosen, 2005; Sotoca et al., 2008). ERβ expression and agonist stimulation
slows the growth of cells (Hodges-Gallagher et al., 2008; Paruthiyil et al., 2011).
When the balance of the receptors in the cell leans towards more ERβ than ERα,
proliferation is repressed (Gougelet, Mueller, Korach, & Renoir, 2007). I have
observed that increasing the balance of ERβ expression does abate proliferation
through my own experience cultivating the MTO ERβ cells without dox when
compared to MTO ERβ cells maintained in dox.
Three cell lines stood out as examples of ERα and ERβ expressing,
predominantly ERα expressing or predominantly ERβ expressing. The
complement of Estrogen Receptors in cells is important because the ratios of
receptors influences cell growth (Helguero et al., 2005) as well as the ability of a
cell to respond to specific Estrogen Receptor agonists (Marzagalli, Casati,
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Moretti, Montagnani Marelli, & Limonta, 2015). T47D was chosen because it
expressed both ERα and ERβ in qPCR and western blots. Western blots using
the cell line MCF-7 showed that it had ERβ, but mRNA expression suggests that
MCF-7 is primarily an ERα expressing cell line because little ESR2 is expressed.
Also, we do not have a lot of confidence in the ERβ antibody (PA1-310B), as
discussed in chapter 2, therefore we regard MCF-7 as primarily ERα. Finally
HCC1937 was chosen because both the ERβ protein and the ratio of ESR2:
ESR1 in qPCR was surprisingly high, which led us to regard it as a predominantly
ERβ expressing cell line.
The objectives of these experiments using the cell lines are to compare
responses in each cell line type (ERα and ERβ expressing, ERα expressing and
ERβ expressing) to different receptor agonists in terms of proliferation responses
and potential genome surveillance. ERα and ERβ directs the transactivation of
estrogen response genes in the cell including genes that modulate proliferation
and genomic surveillance (Lattrich, Juhasz-Boess, Ortmann, & Treeck, 2008).
The progesterone receptor is one of the downstream targets of ERα and its
upregulation is correlated to a ligand-activated ERα (Flötotto et al., 2004; Saji et
al., 2002). Amphiregulin (AREG) is an important growth factor that is also
induced by estrogen through ERα stimulated signaling (Ciarloni, Mallepell, &
Brisken, 2007). This member of the epidermal growth factor (EGF) family signals
in a paracrine fashion through the EGF receptor to stimulate proliferation. AREG
upregulation is also associated with hyperplasia in breast cancer in humans and
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mice (Lee et al., 2007; Niemeyer, Spencer-Dene, Wu, & Adamson, 1999). The
expression of TGFβ2 and CEBPd indicate induction of genomic surveillance.
Transforming growth factor- beta 2 (TGFβ2) is a cytokine that once bound to its
membrane receptor, initiates the intercellular recruitment of a complex of
activated Smad proteins that interact with DNA to transactivate genes involved in
cell cycle arrest and apoptosis (Massagué, 2008). CEBPd, a member of the
CCAAT transcription enhancer binding proteins, has been indicated as a good
prognostic marker for long progression free survival in patients with ERα positive
breast cancer (Mendoza-Villanueva et al., 2016). Also, in MCF-7 and other breast
cancer cell lines, CEBPd was also found to promote differentiation and inhibit
growth through the down regulation of cyclins (Pawar et al., 2010). The
quantification of these transactivation markers after the acute agonist treatment,
with different complements of Estrogen Receptors as context, will help elucidate
ER mediated cell fate.
Materials and Methods
Cell Culture: All cells were cultured at 37°C and 5% CO2. Each Cell line was
expanded in their standard Dulbecco’s Modified Eagle’s Medium/Nutrient mixture
F1-12 Ham (DMEM:F12, Sigma-Aldrich; St. Louis, MO) with 15 mM NaHCO3 and
25 mM Hepes. Three days before plating for each treatment (in triplicate), the
media was switched to phenol red-free (prf) DMEM:F12 media with 5% Charcoal
Stripped Fetal Bovine Serum (CS-FBS, Sigma-Aldrich; St. Louis, MO). Cells were
plated either at 500,000 cells/well or 1,000,000 cells/well in a six well plate (Cell
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Treat; Shirley, MA) at 50-60% confluence in order to achieve optimum 75-80%
cell density at time of harvest. One day after plating the serum was reduced to 1
or 2% CS-FBS. After incubating for 24 hours in 1 or 2% CS-FBS media, cells
were treated with the agonists at the concentrations indicated (Figure 3.1) in prf
DMEM:F12 media with 1 or 2% CSS. Cells were treated with either E2 (Sigma
Aldrich; Cat# E27858), PPT (R&D Systems; Cat#1426-50), ERB041 (R&D
Systems; Cat# 4276-50 in combination with ICI (Sigma Aldrich; Cat# I440925MG). The cells were harvested for mRNA or lysates after 24 hours of
treatment. To repress the expression of ERβ in the MCF-7 tet off cells, cells were
maintained in 50 ng/ml Doxycycline (Dox)(Sigma-Aldrich; St. Louis, MO).
mRNA isolation and RT-qPCR: mRNA isolation and RT-qPCR was described
previously in chapter 2 and primer pairs are listed in Figure 3.2. Gene expression
is shown relative to an IRC and the two-sided Student’s t-test was used to
determine differences between each agonist treatment together with ICI against
the control treated with ICI. P-values of <0.5 (*) was considered significantly
different; <0.01 (**) considered highly significantly different. Error bars indicate
SEM.
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Results
Treatment with 10nM ICI 182,780 suggests potential contaminating
estrogens in cell culture

Although, there was a significant increase in AREG expression in T47D
cells treated with Estrogen Receptor agonists E2, PPT and ERB041 compared to
untreated T47D cells (Figure 3.3 a), treatment with 10nM ICI also significantly
decreased AREG expression. We found that 1nM E2 treatment as well as all
doses of PPT significantly increased AREG expression. ERB041 was able to
increase AREG expression in T47D cells only at the lowest dose (20nM), while
the higher doses were not significant. Whereas the differences are considered
significant with the t-test, the fold change increase is small, with between 0.5 to 2
-fold increments and there was no observable dose dependent effect. We found
no significant effect in terms of PR expression in MCF-7 cells using the same
Estrogen Receptor agonists (Figure 3.3 b). However, treatment with 10nM ICI
also significantly reduced PR expression relative to the untreated control. The
reduction in expression of AREG and PR expression in the presence of 10nM ICI
signifies that the culture conditions may contain an unknown estrogenic
compound that is increasing background AREG and PR expression in the T47D
and MCF-7 cells.
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Effect of Agonists on gene expression in T47D cells
Because we detected background estrogenic activity that could be
reduced with 10nM ICI, T47D cells were treated with ICI in conjunction with
agonists to observe differences in mRNA expression. E2 treatment significantly
increased the expression of AREG in a dose dependent manner (Figure 3.4 a)
Although 1nM PPT significantly decreased AREG expression (p=0.03); PPT at
the highest doses, similar to E2, increased expression of AREG in a dose
dependent manner. Interestingly, the ERβ agonist, ERB041, significantly
decreased the expression of AREG in T47D cells, signifying that specific
activation of ERβ repressed this growth factor. We also analyzed the expression
of two presumed estrogen regulated genes that could potentially restrict cell
growth. TGFβ2 was significantly suppressed by E2 (Figure 3.4 b) both at 1nM
and 10nM E2. The background xenoestrogens in the culture conditions also
suppressed TGFβ2 expression in the control without ICI, but 10nM ICI releases
this repression. Low doses of PPT did not repress TGFβ2, but high doses
(500nM) of PPT significantly repress TGFβ2. Although the expression of TGFβ2
at the highest ERB041 concentrations (5000nM) was decreased, this may be
mediated through ERα, rather than ERβ because high concentrations of ERB041
can have agonist effects on ERα. CEBPd, a potential marker for cell cycle
inhibition also appeared to be inhibited in the control cells without ICI and again
repression was relived by treatment with ICI (Figure 3.4 c). High doses of E2
(10nM) and PPT (500nM) were able to suppress CEBPd expression while lower
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doses of the ERα agonists did not significantly change expression. ERB041, the
ERβ agonist, increased CEBPd expression in T47D cells at 500nM, but not at the
low or high concentrations.
Effect of Agonists on gene expression in MCF-7 cells
AREG expression by background estrogens is again blocked by ICI
treatment in the MCF-7 cells (Figure 3.5 a). E2, at both the 1nM and 10nM
concentrations, was able to significantly increase AREG expression in a dose
dependent manner. Interestingly, all three doses of PPT increase the expression
of AREG in the presence of ICI, but there was a slight decrease in expression,
from about 20 fold at the highest dose (500nM) to about 17-fold difference
(50nM) over ICI control. ERB041 at lower doses does not increase expression of
AREG except at the highest dose (5000nM), however, at high dose (5000nM),
ERB041 did increase AREG expression significantly, probably because it is able
to cross-react with ERα. There was no significant TGFβ2 (Figure 3.5 b) or
CEBPd (Figure 3.5 c) response to the agonists even though the 500nM dose of
PPT seems to decrease TGFβ2 in MCF-7 cells.
Effect of Agonists on gene expression in HCC1937 cells
Next, we used the Estrogen Receptor agonists in HCC1937 cells to
evaluate their transcriptional responses. There was no significant change is
expression of AREG (Figure 3.6 a), TGFβ2 (Figure 3.6 b) or CEBPd (Figure 3.6
c) in response to agonists. Appraisal of the ct values in the qPCR showed that
there were several factors that caused variability in our results. There were a
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large number of outlying ct values as well as a wide range of ct value variance in
the samples that contributed to the standard error mean. More specifically, the
variance within treatment groups was mirrored for the gene expression of each of
the three genes, suggesting that quantification of the RNA was inaccurate. This
experiment should be repeated because we expect that HCC1937 cells, a
predominantly ERβ expressing cell line, will not be able to be stimulated by the
agonists and therefore will not be able to express the ERα regulated gene AREG.
Whereas, the ERβ agonist ERB041 may increase TGFβ2 and CEBPd
expression, E2 and PPT should not be able to repress the expression of these
genes.
Comparison of AREG, TGFβ2 and CEBPd expression to E2 treatment in
three cell lines
Because we chose cell lines to represent three different estrogen receptor
ratios: (1) expressing both ERα and ERβ, (2) primarily ERα expressing and (3)
primarily ERβ expressing, we wanted to compare estrogen responses across the
three cell lines. The ERα and ERβ expressing T47D cells as well as the ERα
expressing MCF7 cells responded to increasing doses of E2 by expressing
AREG in a dose dependent manner (Figure 3.7 a). There was a highly significant
(p< 0.001) difference of in magnitude of AREG expression in both the 1nM and
20nM E2 treated T47D and MCF7 cells, such that AREG induction by E2 is
greatest in the MCF-7 cell line, which expresses primarily ERα. We found that the
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predominantly ERβ expressing cell line HCC1937 had significantly reduced
AREG expression compared to the cell lines with ERα.
Curiously, TGFβ2 was significantly increased in the ERα expressing MCF7 cell line in comparison to both the ERα/ERβ expressing cell line T47D an the
ERβ alone expressing HCC1937 cell line (Figure 3.7 b). There was no difference
in TGFβ2 expression between T47D cells and HCC1937 cells. Interestingly,
expression of CEBPd is significantly greater in cells that express ERβ only
(HCC1937) relative to cells that also express ERα and ERβ (T47D) or ERα
(MCF7) only (Figure 3.7 c).
Discussion
In our initial experiments, we found that ICI significantly decreased the
expression of AREG and PR, known ERα responsive genes, suggesting that
background estrogens were contributing to ERα mediated gene transcription.
This background activity obscured our ability to measure dose dependent
responses (AREG) or any responses to agonists at all (PR).
Finding background estrogen activity in our cell culture system is a hazard
of working with plastics that may leach xenoestrogens into our cell culture dishes
(Sax, 2010). These xenoestrogens mimic the activity of naturally occurring
estrogen to the point of obscuring estrogenic activity in signaling pathways on the
genomic and non-genomic level (Jeng, Kochukov, & Watson, 2010). This is
important because cell culture supplies could be contributing to a false result.
Investigators are aware of the estrogenic effects of phenol red and estrogen in
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serum, but other factors could be present and should be tested for and controlled
in estrogen related research models. Our results show that is important to test for
background estrogen activity in cell culture, and in our case, ICI decreased
significant background estrogenicity.
Using ICI to block background estrogen, we were able to detect significant
dose-dependent responses to the agonists in the cell line that expressed both
receptors – T47D. The proliferation maker, AREG, increased by E2 and PPT, but
was decreased by the ERβ specific agonist ERB041. The expression of growth
restrictive markers (TGFβ2 and CEBPd) decreased in the presence of E2 and
PPT. Whereas, ERB041, the ERβ agonist may stabilize or increase expression.
This indicates that cells that express both ERα and ERβ have a balance of
proliferation and growth restriction through the two receptors. Further, cells that
express primarily ERα, like MCF-7, also induce dose dependent increases in
AREG expression in response to E2 and PPT. However, none of the agonists
induced any change in expression of TGFβ2 or CEBPd.
Interestingly, the magnitude of AREG expression in the primarily ERα cell
line was significantly increased relative to T47D cells which express both
estrogen receptors. This indicates the importance of the presence of ERβ to
modulate expression of AREG and proliferation. Although the analysis for
HCC1937 needs to be repeated, the current data demonstrates two
characteristics (1) AREG expression is not induced and is relatively low in the
primarily ERβ HCC1937 cell line (the cells grew painfully slow) and (2) the
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magnitude of CEBPd is elevated in the HCC1937 line relative to both ERα and
the ERα/ERβ expressing cell lines.
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Treatment
ICI 182,780

Working
Concentration
10 nM

Receptor
Action/Affinity
ERα Antagonist

17 β-estradiol
(E2)

1ηM or 10ηM

Equal agonist/affinity
for both receptors

4,4',4''-(4Propyl-[1H]pyrazole-1,3,5triyl)trisphenol
(PPT)

5ηM - 1000ηM

ERα Agonist

7-Ethenyl-2-(3fluoro-4hydroxyphenyl)5-benzoxazolol
(ERB041)
50ηM - 5000ηM

ERβ Agonist

Figure 3.1 Agonist Table. Cell culture treatments for all experiments
at the concentrations indicated.
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Figure 3.2 Primer pairs used in qPCR
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a

AREG expression in T47D cells in reponse to agonists
8

**

Expression Rela>ve to IRC

7
6

**

5

**
**

**

**

4
3

**

2
1
0
Control
no ICI

10nm ICI

1nm

10nm

20nm

100nm

E2

200nm 1000nm

20nm

PPT

100nm

200nm 1000nm

ERB041

Progesterone Receptor expression in MCF7 cells in response to
agonists

b
0.35
0.3
0.25
0.2
0.15
0.1

**

0.05
0
Control

10nm ICI

1nm

10nm

20nm

100nm

E2

200nm

PPT

1000nm

20nm

100nm

200nm

1000nm

ERB041

Figure 3.3 qPCR for AREG in T47D cells (a) and PR expression MCF7
cells (b) without ICI treatment. * p <0.05; ** p<0.01
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a
**

**

**
**

*
**

**

**

**

b

*
**

**

**

**

**

c
**

**

**

**

Figure 3.4 RT-qPCR in T47D cells treated with Estrogen Receptor
agonists to measure AREG (a), TGFβ2 (b) and CEBPD (c)
expression. * p< 0.05; **p< 0.01

55

a
**

**
**

**
**
**

**

b

c

Figure 3.5 RT-qPCR in MCF7 cells treated with Estrogen
Receptor agonists to measure AREG (a), TGFβ2 (b) and
CEBPD (c) expression. * p< 0.05; **p< 0.01
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a

AREG expression in HCC1937 cells in response to
agonists
Expression rela?ve to IRC

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1nM
Control

Control

10nM

5nM

E2

PPT

no ICI

b

50nM 500nM 50nM 500nM 5000nM
ERB041

10nM ICI

Expression rela<ve to IRC

TGFb2 expression in HCC 1937 cells in response to
agonists
20
18
16
14
12
10
8
6
4
2
0
1nM
Control

Control

10nM

5nM

E2

PPT

no ICI

c

50nM 500nM 50nM 500nM 5000nM
ERB041

10nM ICI

CEBPd expression in HCC1937 cells in response to
agonists
Expression Rela<ve to IRC

16
14
12
10
8
6
4
2
0
1nM
Control

Control

10nM

5nM

E2

50nM 500nM 50nM 500nM 5000nM
PPT

no ICI

ERB041

10nM ICI

Figure 3.6 RT-qPCR in HCC1937 cells treated with Estrogen
Receptor agonists to measure AREG (a), TGFβ2 (b) and CEBPD
(c) expression.
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AREG expression in response to 17β-estradiol

TGFβ2 expression in response to 17β-estradiol
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*

*

15.00

10.00
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10.00
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6.00
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1nM E2 + ICI
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10nM ICI

T47D

8
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T47D
0.90
ERα/ERβ
7
1.25
2.43

6

MCF7

0.43
HCC1937
0.29
ERβ!

9.20

3
2
1
0

!

17.24

Control
10nM ICI

0.39

0.34

T47D

MCF7

T47D
1.30
ERα/ERβ
2.60
1.13

10.16792347

3.412429879

10nM E2 + ICI

1.03

8.643230612

3.042570861

Control

8
7

10nM ICI

6
5

1nM E2 + ICI

4

ns

3
2

10nM E2 + ICI

MCF7

1

HCC1973

Control

0.6092975180

10nM ICI

Control
0.950344886

0.609297518
1.097195699
ERα/ERβ
ERα
0.979201403

1nM E2 + ICI

1.221469856
1nM E2 + ICI

1.2214698561.486739253
1.486739253

10nM ICI

HCC1937
1.933621196
ERβ!
3.583425817

**

9

T47D

HCC1973

MCF-7
5.13487982
ERα
7.346208488

1nM E2 + ICI

CEBPd expression in response to 17β-estradiol

5
4

0.00

HCC1937

14.92
MCF-7
0.97
ERα

Expression RelaBve to IRC

0.00
Control

2.00

T47D
T47D

1.097195699
MCF7
MCF-7
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HCC1973
HCC1937
6.542110815
ERβ!
5.268846385

!
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5.388308935
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10nM E2 + ICI
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1.323592002
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10nM E2Figure
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5.329592604
3.7
Comparison
of RT-qPCR
expression
in three cell lines

* p< 0.05; **p< 0.01
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CHAPTER 4
THE βERKO MOUSE MODEL TO EXPLICATE THE HISTOLOGIC AND GENE
EXPRESSION PROFILES OF ACUTE AGONIST EXPOSURE IN MOUSE
MAMMARY TISSUE FOR PROLIFERATION AND MARKERS OF
SURVEILLANCE.
Introduction/Rationale
Humans and mice have a 95% exon homology and we share many of the
same genetic diseases (Batzoglou, Pachter, Mesirov, Berger, & Lander, 2000).
Genetic variation in humans and mice can contribute to the development of, or
resistance to tumors. Mammary tumor susceptibility is different among women
and mouse strains. Some women have an alteration in their tumor suppressor
proteins, like BRCA1, that allows unrepaired DNA damage that leads to tumor
formation. This is mirrored in some mouse strains, like BALB/c, which are more
genetically susceptible to mammary tumorigenesis (Kuperwasser et al., 2000). In
contrast, the C57BL/6 are resistant to mammary tumors, even in mammary tumor
induction models including Mouse Mammary Tumor Virus Infection (Okeoma,
Petersen, & Ross, 2009), gamma-irradiation, and even when the tumor
suppressor protein p53 is knocked out (Yan et. al., 2010).
Women vary in their estrogen receptor ratios and in their responses to
hormones (Dunphy unpublished). Further, the ratios of estrogen receptors shift
and the expression of ERα increases while ERβ decreases as a women age,
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potentially leading to a shift in the range of ER-hormone mediated responses.
Mouse strains also exhibit different ER ratios and hormone responses. For
example, ERα expression is greater in BALB/c when compared to C57BL/6,
while ERβ expression is similar. This means that the BALB/c mouse strain has a
more unfavorable ER ratio, which may potentiate tumorigenesis through ERα
mediated proliferation (Montero Girard et al., 2007). C57BL/6 mice have reduced
hormone-induction of RANKL (cytokine of survival, proliferation) and ID2
(negatively regulates cell differentiation), but elevated p21 (growth arrest) relative
to BALB/c mice in which p21 is decreased by hormone treatment (Aupperlee et
al., 2009).
These experiments are to compare the different responses to various
estrogen receptor agonists in terms of growth and radiation-induced apoptosis in
the C57BL/6 mouse mammary gland in the context of different estrogen receptor
ratios: Wt C57BL/6 with equal ERα: ERβ expression vs. βERKO C57BL/6 with
ERα expression but no ERβ, and to compare these responses to the BALB/c
strain which has high ERα: ERβ ratios. The βERKO strain of mice were
developed by Krege et. al. and have a deleted exon 3, the DNA binding domain
of ERβ. This deletion results in a non-functional ERβ. The experiments in the
βERKOs will demonstrate the specificity of the ERβ agonists.
Materials and Methods
Animal Models: Mice colonies were maintained in standard cages with ad libitum
access to water and mouse diet 5015 in an animal facility on a daily 12-hour
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light/dark cycle. ERβ knockout (βERKO) mice were generated by the Korach
laboratory (Krege et al., 1998) with genetic disruption in Esr2 (B6.129Esr2tm1.1Ksk) were used in our experiments. These mice were generously donated
by Dr. Ken Korach. The knockout allele was maintained on a C57BL/6
background. Female mice were ear notched for the dual purpose of identification
and genotyping at the time of weaning, aged 21 days. Ear notch tissue was held
at -20°C until DNA extraction.
Preparation of agonist pellets: Pellets were made using silastic tubing (Fisher, #
11-189-15H) sealed with silicone (DAP Inc, # 070798006881) approximately 1.2
cm long. These were packed with either cellulose alone as a control or cellulose
plus one of four compounds: control (Fischer, # AC382312500), E2 (50μg; Sigma
Aldrich;Cat# E27858), PPT (400μg; R&D Systems, Cat# 1426-50), ERB041
(400μg; R&D Systems; Cat# 4276-50). The proper ratio of cellulose to hormone
was combined prior to packing the capsules and then each capsule was packed
with compound so each would contain the appropriate concentration of the
specified agonist. The pellets were sterilized with 5kGy gamma irradiation and
primed in standard phenol red-free DMEM:F12 media (Sigma Aldrich; # D2906)
for 24 hours prior to implantation.
βERKO C57BL/6 female mice: Virgin female mice were ovariectomized at 8-12
weeks of age and endogenous hormones were allowed to clear for two weeks
(Figure 4.1). The βERKO mice were treated with individual silastic capsules
packed with 50 μg of E2, 400 μg of PPT, 400 μg of ERB041 or a control silastic
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capsule containing cellulose. The silastic capsules were implanted
subcutaneously into the mouse dorsum and the mice were allowed to be in
contact with treatments for 96 hrs. Following the treatment period, the animals
were subjected to 5 Gy whole-body ionizing radiation using a 137Cs source. Mice
were given an intraperitoneal injection 4 hours post irradiation of 100-200 µl of a
BrdU (Bromodeoxyuridine) -containing solution (10 mg/ml solution of BrdU in
sterile 1X PBS). Tissues were harvested 6h post-irradiation. At the end of the
treatment period the 4th inguinal mammary glands were harvested, the lymph
nodes removed and the tissues was flash frozen in liquid nitrogen for RNA. Blood
was collected and allowed to coagulate for serum. The contralateral gland was
fixed for whole mounts. The third mammary gland and other tissues including
skin, colon and uteri were collected and were formalin-fixed and paraffin
embedded for histology. All animal procedures were in accordance with
institutional and national guidelines for the use of animals and were approved by
the Institutional Animal Care and Use Committee at the University of
Massachusetts-Amherst.
PCR genotyping primers design and amplicon analysis: DNA from mouse ear
notch tissue was isolated using KAPA Express Extract enzyme (KAPA
Biosystems; Boston, MA). In brief, tissue digestion was achieved using ~1 mm
mouse tissue, PCR grade H2O, 1U/μl KAPA Express Extract Enzyme and 10X
KAPA Express Extract Buffer (KAPA Biosystems; Boston, MA) using the
following parameters: 20 minutes at 75°C, 8 minutes at 95°C. Following brief
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voretxing, ear notch debris was pelleted. PCR was performed using primer pairs
listed in Figure 4.2. The typical 11 μL PCR reaction mix contains nuclease free
water, 1X KAPA2G Fast Genotyping Mix (KAPA Biosystems; Boston, MA) , 0.5
μM mutant reverse primer, 0.5 μM wild type reverse primer, 0.5 common primer
and genomic DNA template (<1 μg). The standard PCR condition was as follows:
95°C for 5 min; 95°C for 15 s, 64°C for 15 s, 72°C for 20 s for 35 cycles; 72°C for
8 min followed with denaturation for 5 minutes at 95°C. PCR products were
removed from the thermocycler and maintained at room temperature for at least
5 minutes allowing for annealing. PCR products were resolved with ethidium
bromide-stained 1% agarose gel.
Wholemount Preparation: Whole inguinal mammary glands (gland # 4) were
spread on glass slides, fixed in Carnoy's solution (60% absolute alcohol, 30%
chloroform and 10% acetic acid), stained overnight in Carmine alum solution
(2g/L carmine; 10mM aluminum potassium). Glands were dehydrated in graded
ethanol, cleared in xylenes and mounted on slides with permount.
Results
Previous work done in the lab by Erick Roman-Perez compared
proliferation and radiation-induced apoptosis in C57BL/6 WT and βERKO mice
that were treated with vehicle control or E2 (50mg) for 4 days. The WT C57BL/6,
which has both estrogen receptors, had a better apoptotic response than the
βERKO, which only has ERα. I will build upon the previous work in the C57BL/6
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and βERKO mice by including the ER agonists PPT, ERB041 along with E2 and
a control.
βERKO mouse genotyping
We developed a βERKO mouse specific genotyping protocol using one
primer set consisting of a mutant reverse, wild type reverse and common primer
for amplification of mouse ERβ (Figure 4.2). Our primer set was designed to
produce an ERβ specific PCR product of two DNA fragments with a large size
difference (~730bp and 407bp). In our experiments we found that the PCR
resulted in three distinct bands for the heterozygote mice at about 700bp, 600bp
and 400bp (Figure 4.3). The weaker upper band (~700bp) with heterozygote
mice is due to the competition of both templates for the same primer pair. Wild
type mice DNA produced a PCR product at ~600bp and ~400bp. This is in
contrast to the ERβ null mice which produced two bands, one at ~700bp and the
other ~600bp. There was a clear distinction between the bands however, and the
genotyping results were unambiguous.
βERKO mice database
In order to track the treatment history of each βERKO mouse test subject
we developed a cloud-based database (Figure 4.4). Each female mouse received
an identifying number via ear notch upon weaning. This number was associated
with the mouse date of birth, ovariectomy date and hormone treatment. A second
number was assigned to the mice upon tissue collection. This id was used for
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identification of histological samples (mammary gland whole mount, H&E and
serum), assays (TUNEL and BrdU) as well as RNA samples used for qPCR.
Areg is upregulated by E2
Preliminary data from fourth gland mammary tissues in ERβ knockout
(βERKO) mice show that E2 was able to upregulate the expression of Areg, a
marker of ERα activated proliferation, about 150-fold over untreated control
tissues (Figure 4.5). PPT, the ERα selective agonist, failed to increase Areg
expression in the βERKO mouse mammary tissues. This result is in contrast to
previous studies in which PPT increased Areg expression to 50% of E2. Finally,
because Areg is a marker of ERα activation, we do not expect the ERβ agonist to
work in the βERKO mice for two reasons: (1) βERKO mice do not have a
functional ERβ receptor and (2) the ERβ agonist ERB041 cannot act through a
non-functional receptor. In agreement with Areg expression, the mammary
epithelial ducts are thinner for the control, PPT- or ERB041-reated relative to the
E2-treated in representative whole mount images (Figure 4.6).
Discussion
It was expected that E2 would be able to activate ERα in βERKO mice.
The lack of Areg response to PPT in the mouse tissues was an unexpected
result. Previous work by Erick Roman-Perez measured Areg in BALB/c mice that
were treated with vehicle control, E2, PPT and DPN for 4 days. E2 increased the
expression of Areg almost 200-fold and PPT increased expression almost 150fold over control, while DPN-treatment did not. In that study the Jerry lab used
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sesame seed oil as a carrier for hormone injections and the hormone was
prepared fresh daily from stock held at -20°C in ethanol. Because daily hormone
injections with sesame seed oil could be inconsistent and required more animal
handling, the Lab adapted their hormone delivery methods and began using
hormone mixed with cellulose packed in silastic capsules. Since then, changes to
OLAW regulations for animals were implemented that required all surgically
implanted hormone delivery devices to be sterilized. That meant that PPT, which
should be stored at -20deg, would be packed into silastic capsules with cellulose
and irradiated (5 Gy) for 48 hours at room temperature in a Cs-137 irradiator.
Following sterilization the pellets are placed into priming media overnight at 37oC
prior to implantation into the mice. It is possible that the extended amount of time
outside of ideal storage conditions as well as the potential disruption of the
chemical structure through irradiation may have led to the degradation of PPT.
The experiments using PPT will need to be repeated after determining methods
that retain activity.
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FFPE for histology

Ovx
Week 8 -12

Week 12-14

Day 0

Agonist
Ctrl
E2 50µg
PPT 400µg
ERB041
μg
DPN 400µg

IR
Day 4

RNA /cDNA/qPCR

Figure 4.1 Model for βERKO mouse experiments

67

Histology:
TUNEL (apoptosis/surveillance)
BrdU (proliferaFon)
IHC ERα and ERβ
Gene Expression:
ProliferaFon - AREG, PR
Surveillance – TGFβ, CEBPD

cDNA

Primer

Mutant Reverse Mouse ERβ

5’-GTTGGCAGGGAAAGTTGAAAAC-3’

Size of
Product
730 bp

Wild Type Reverse Mouse ERβ

5’-AGTAACAGGGCTGGCACAAC-3’

407 bp

Common Mouse ERβ

5’-TCCCCAAAAGAAACATGTCC-3’

Figure 4.2 Genotyping primers: oligonucleotide primer names, sequence, and
orientation are shown.

68

2 log
DNA
Ladder
1

Lane
2

3

+/- +/-

4

-/-

5

-/-

6

+/-

7

8

9

-/- +/- -/-

Figure 4.3 Example of genotyping results
+/+ Wild type ERβ
-/- Null (no ERβ)
+/- Heterozygous ERβ
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10

11

12

13

+/- +/- +/+ -/-

14

+/-

tissue id
5115
5116
5117
5118
5119
5120
5121
5123
5124
5125
5126
5127
5145
5146
5147
5148
5149
5150
5152
5153
5154
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AREG Expression in BERKO mouse mammary gland in response to
agonists
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Figure 4.5 RT-qPCR in mouse mammary gland tissue
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Figure 4.6 Representative βERKO Mouse mammary gland whole
mounts harvested 4 days post agonist treatment.
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CHAPTER 5
CONCLUSION
Breast cancer cell lines are used as a reference for both agonist induced
Estrogen Receptor mediated gene expression as well as elucidating potential
therapeutic targets in human breast cancer (Eric, Jennifer, Fernando, & Jordan,
2006; Haldosén, Zhao, & Dahlman-Wright, 2014; Helguero, Faulds, Gustafsson,
& Haldosen, 2005). In this study of ER mediated balance between proliferation
and growth modulation in human breast cancer, we began by characterizing the
Estrogen Receptor status as well as the ratio of ERα to ERβ in six immortalized
breast cancer cell lines: T47D, MCF-7, MDA MB 231, MTO ERβ, HCC1937,
ZR75-1 and one immortalized “normal” breast cell line 76N tert. We endeavored
to link the balance of Estrogen Receptors in these cell lines to ER specific
agonist stimulation in order to measure the response through ER protein and
gene target expression. For ERα responses we used well-established ERα
targets AREG and PR. And to gauge the repressive effects of ERβ stimulation we
used CEBPd and TGFβ2. Then, in order to observe in vitro mammary gland
responses to ER specific agonists, we utilized an ovariectomized ERβ knockout
mouse model.
After determining the baseline expression of ER through qPCR and
western blots in our reference breast cancer cell lines, we compared the
responses to ER agonists. We were able to make several observations about our
reference cell lines based on our results. First, we determined that T47D cells
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express both ERα and ERβ by gene and protein expression. Our data also
indicates that E2 and PPT upregulated the ERα responsive gene AREG in a
dose dependent manner. We observed that ERα expression in T47D cells
repressed TGFβ2 and CEBPd expression. Secondly, we found that MCF-7 cells
express primarily ERα. In MCF-7 cells, the ER agonist E2 significantly increased
the magnitude of AREG expression compared to T47D cells. We believe that in
MCF-7 cells, with unopposed ERα expression increases the responsiveness of
the cell to E2-mediated proliferation. Next, we observed that HCC1937 cells
primarily express ERβ. Also, the HCC1937 cell line expresses high endogenous
levels of CEBPd, the potential marker for cell cycle arrest, relative to both ERα
and the ERα/ERβ expressing cell lines.
Frustratingly, we observed several results that will have to be resolved in
the future. Among the results is that our western blot data indicate that a reliable
ERβ antibody remains elusive. Our western blot data is questionable for three
reasons. First, the MTO ERβ overexpressing and HCC1937 cell lines had
erroneously low ERβ protein expression despite having high and moderate qPCR
expression respectively. Secondly, we observed the slow growth pattern of these
two cell lines, which is typical of ERβ expressing cells, so we are confident that
they are expressing ERβ protein. And finally, the protein band for the “ERβ”
antibody observed on the blot was not the correct calculated molecular weight.
Among the western blot results we were also surprised to find that we may have
contamination of our ZR75-1 cell line. This may have caused the low ERα
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expression observed in this traditionally ERα positive cell line. Another result that
will need to be addressed is in regard to the in vivo experiments in the βERKO
mice. Our results indicate that the low expression of PPT induced AREG
observed in qPCR may be due to the thermo instability of PPT for the extended
period of time needed for irradiation-based sterilization prior to in vivo testing.
In the future, our lab will choose new cell lines that express ERα primarily,
ERβ primarily and express both ERα and ERβ to test responses to Estrogen
Receptor specific agonists. We will also retry PPT treatments in βERKO mice as
well as in wild type mice. We will also run qPCR on the harvested βERKO
mammary tissue in order to determine the expression of CEBPd and TGFβ2.
To conclude, ERα and ERβ are just parts of the dynamic tension that
determines breast cancer cell proliferation and cell cycle arrest. Building upon the
results presented here, we hope to improve our understanding of the Estrogen
Receptor status of our reference cell lines for future use.
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